PD-L1 in malignant pleural effusions
Alex Soltermann
Department of Pathology and Molecular Pathology
Lung adenocarcinoma, cT2b, cN2, cM1a, stage 4
PET-CT: centrally necrotic tumor right upper lung lobe, pleural infiltration, pleura carcinosis, massive effusion with subtotal atelectasis and eventual lymph node metastases hilar ipsilateral and mediastinal
Effusion cytologies (2 samples): TTF1+ lung adenocarcinoma
Mol Path: KRAS p.G12C exon 2
ECOG status 0 (fully active, able to carry on all pre-disease performance)
→ Cisplatin/Pemetrexed
Pat 68 yrs, 50 pys, 10/2015
• E1L3N antibody on Leica Bond automat
• Weak membranous immunoreactivity in >10% of tumor cells
• Category 3
01/2016 PD-L1 IHC
German PD-L1 harmonization trial
Tonsil, E1L3N, 100x
Effusion 1, E1L3N, 100x, Cat. 5
Effusion 2, E1L3N, 100x
Tonsil, SP263, 100x
Effusion 1, SP263, 100x
Effusion 2, SP263, 100x
Tonsil, DAKO 22C3 on Ventana
Effusion 2, DAKO 22C3 on Ventana